NCT02326584 (Clinical Trial/ Vadastuximab Talirine)

Study Title

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML (NCT02326584)

Trial Description

This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) by itself (monotherapy) or in combination with other standard treatments. The main purpose of this study is to find the best dose and schedule for SGN-CD33A when given in combination with standard induction treatment, in combination with standard consolidation treatment, or by itself for maintenance treatment.

This will be determined by observing the dose-limiting toxicities (the side effects that prevent further increases in dose) of SGN-CD33A. In addition, the pharmacokinetic profile and anti-leukemic activity of the study treatment will be assessed.

This trial is sponsored by Seattle Genetics, Inc.

Study Data

  • Condition:
    • Acute Myeloid Leukemia
    • Acute Myelogenous Leukemia
  • Interventions:
    • Drugs used in this trial
      • Standard dose cytarabine for induction
      • SGN-CD33A
      • Daunorubicin
      • High dose cytarabine for consolidation
  • Phase: I
  • Estimated Enrollment: 144
  • Start: December 2014
  • Estimated Completion: December 2017
  • Last verified: January 2016
  • Last updated: January 2016

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: February 22, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.